Palonosetron Accord

Palonosetron, the active ingredient in Palonosetron Accord, is a 5-HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Accord is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways related to cancer therapy and surgery. - Chemotherapy‑induced nausea and vomiting (CINV): helps prevent acute and delayed episodes in patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: mitigates nausea associated with abdominal or pelvic radiation treatments. - Anticipatory nausea and vomiting: lessens nausea that patients may experience before chemotherapy based on prior experiences.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT interval prolongation: cardiac rhythm changes detectable on ECG. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, fever, tremor when combined with serotonergic agents. - Cardiac arrhythmias: irregular heartbeats beyond QT changes. - Neuro‑muscular weakness: rare muscle tone alterations.

When prescribing Palonosetron Accord, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: evaluate for potential serotonin syndrome. - Renal impairment: adjust considerations for patients with severe kidney dysfunction. - Hepatic impairment: use caution in patients with liver disease. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Palonosetron may interact with other medications, requiring attention to the following categories.

Major Interactions (Avoid): - QT‑prolonging agents: concurrent use may increase risk of cardiac arrhythmias. - Potent CYP3A4 inhibitors: may raise palonosetron plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic antidepressants (SSRIs, SNRIs): monitor for signs of serotonin syndrome. - Anticholinergic drugs: may enhance constipation. - Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm. - Antifungal azoles: potential modest increase in exposure. - Opioid analgesics: may compound central nervous system depression.